This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to
About the Federal Register
on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.
Notice
Enter a search term or FR citation e.g.
88 FR 38230 FR 78782024-13208USDA09/05/24RULE0503-AA39SORN
Choosing an item from
full text search results
will bring you to those results. Pressing enter in the search box
will also bring you to search results.
Choosing an item from
suggestions
will bring you directly to the content.
Either electronic or written comments on the notice must be submitted by June 30, 2026
Table of Contents
Enhanced Content - Table of Contents
This table of contents is a navigational tool, processed from the
headings within the legal text of Federal Register documents.
This repetition of headings to form internal navigation links
has no substantive legal effect.
Comments are no longer being accepted.
See DATES for details.
69 comments have
been received at Regulations.gov.
Agencies review all submissions and may choose to redact, or withhold,
certain submissions (or portions thereof). Submitted comments may not be
available to be read until the agency has approved them.
Docket Title
Document ID
Comments
Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments
FederalRegister.gov retrieves relevant information about this document
from Regulations.gov to provide users with additional context. This
information is not part of the official Federal Register document.
Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments
Document page views are updated periodically throughout the day and are
cumulative counts for this document. Counts are subject to sampling,
reprocessing and revision (up or down) throughout the day.
Page views
2,582
as of
11/18/2026 at 6:15 pm EST
Other Formats
Enhanced Content - Other Formats
This document is also available in the following formats:
This PDF is FR Doc. 2026-08524 as it appeared on Public Inspection on
04/30/2026 at 8:45 am.
It was viewed
59
times while on Public Inspection.
If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507.
Learn more here.
Published Document: 2026-08524 (91 FR 23426)
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice; establishment of a public docket; request for information and comments.
SUMMARY:
The Food and Drug Administration (FDA, the Agency, or we) is establishing a public docket to collect examples about how previous patient-focused drug development (PFDD) meetings have impacted stakeholders' drug development efforts. This includes impacts on community engagement, research priorities, advocacy strategies, medical product development programs, clinical practice, and other areas of interest.
DATES:
Either electronic or written comments on the notice must be submitted by June 30, 2026
ADDRESSES:
You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The
https://www.regulations.gov
electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of June 30, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to
https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on
https://www.regulations.gov.
If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).
For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”
Instructions:
All submissions received must include the Docket No. FDA-2026-N-3947 for “Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments.” Received comments, those filed in a timely manner (see
ADDRESSES
), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at
https://www.regulations.gov
or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted onhttps://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting
( printed page 23427)
of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at:
https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket:
For access to the docket to read background documents or the electronic and written/paper comments received, go to
https://www.regulations.gov
and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT:
Ethan Gabbour, Center for Drug Evaluation and Research, Food and Drug Administration, 301-796-8112,
Ethan.Gabbour@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
As directed by Section 569C of the Federal Food, Drug, and Cosmetic Act, as amended by Section 3001 of the 21st Century Cures Act (Pub. L. 114-255), FDA has developed and implemented strategies to obtain patient input to inform drug development and regulatory decision-making. FDA-led PFDD and externally led-PFDD (EL-PFDD) meetings provide a structured opportunity to hear directly from patients, caregivers, family members, and patient advocates. These meetings center on the aspects of a disease or condition and its treatment that are most meaningful to patients, including symptoms, effects on daily life, and experiences with available therapies.
Patient input from these meetings can inform medical product development, research priorities, and regulatory oversight. In response to stakeholder requests to better understand the outcomes of these meetings, FDA is seeking to collect information about their subsequent impacts. The Agency recognizes that many significant outcomes such as interactions within patient communities, between patient groups and medical product developers, or among clinicians occur in forums to which FDA is not typically a party. Similarly, changes made by medical product developers in response to patient input may not be communicated to FDA outside of a formal regulatory submission.
II. Issues for Consideration and Request for Information
FDA is issuing this request for information to gain a better understanding of how patient input from FDA-led PFDD and EL-PFDD meetings has informed stakeholder activities including research, product development, and patient care, outside of specific regulatory decisions. FDA invites input from all interested parties, including patient organizations, medical product developers, healthcare providers, and academic researchers.
FDA is seeking information that addresses the following:
1. How have PFDD meetings informed patient communities and stakeholder engagement activities?
2. What scientific questions, research initiatives, or identified gaps in the understanding of a disease or condition have resulted from PFDD meetings?
3. In what ways has patient input from PFDD meetings informed medical product development programs or strategies (
e.g.,
endpoint development, clinical trial design, identification of unmet needs, industry partnerships)?
4. How has patient input gathered during PFDD meetings been integrated into or otherwise affected clinical practice?
5. Please describe any other outcomes or effects resulting from PFDD meetings, with examples, that were not addressed in the questions above.
FDA encourages respondents to provide specific examples in their answers where possible.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
69 comments have been received at Regulations.gov.
Agencies review all submissions and may choose to redact, or withhold, certain submissions (or portions thereof). Submitted comments may not be available to be read until the agency has approved them.